• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Coty Strengthens Consumer Beauty Business With Senior Talent

    12/2/20 3:00:00 AM ET
    $JNJ
    $COTY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $JNJ alert in real time by email

    NEW YORK--(BUSINESS WIRE)--Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced two leaders to drive its Consumer Beauty organization. Stefano Curti will join the company as Chief Brands Officer, Consumer Beauty, while Alexis Vaganay will be promoted to Chief Commercial Officer, Consumer Beauty. The appointments come as CEO Sue Y. Nabi strengthens her leadership team, following the recent additions of Isabelle Bonfanti as Chief Commercial Officer, Luxury, and Jean-Denis Mariani as Chief Digital Officer.

    Stefano Curti joins Coty this week as Chief Brands Officer, Consumer Beauty and will be based in New York. Curti – who has a strong track record of brand building and channel expansions – will focus on strengthening the division’s brand equity, global positioning and innovation performance. He brings a wealth of senior international experience, having spent almost 30 years working in the beauty and health industry in the U.S., Europe and Latin America. Curti joins from Markwins Beauty Brands – the largest independent cosmetics company in the U.S., with established mass cosmetics brands including Physicians Formula, LORAC, Black Radiance and WetnWild – where he served as Global President. He spent 22 years at Johnson & Johnson, where he progressed through the marketing organization to the role of Global President Beauty and Baby divisions. During his time at J&J, Curti led iconic skin and personal care brands like Aveeno, Clean & Clear and Neutrogena, driving above-market sales growth and double-digit profit growth for the beauty portfolio.

    Coty also announced the promotion of Alexis Vaganay to Chief Commercial Officer, Consumer Beauty. Vaganay, who has more than 20 years’ experience in international sales and marketing, takes up his appointment this week and will be based in Coty’s Amsterdam headquarters. He will be responsible for leading Coty’s regions - in close collaboration with his Luxury counterpart - and developing Consumer Beauty’s commercial strategy to increase market share and grow revenues in color cosmetics, body care and consumer fragrances. Most recently, Vaganay was EVP, EMEA, following four years as General Manager of UK&I Luxury. Under his leadership, Coty UK&I was among the fastest growing luxury fragrance players. Prior to joining Coty in 2016, Vaganay worked at Unilever and Bic in a variety of global roles.

    Sue Y. Nabi, CEO of Coty, said, “My ambition from day one has been to quickly build a first-class leadership team. The appointment of these two leaders means we are now in great shape to re-position our portfolio of brands more clearly. Stefano’s track record and sector expertise makes him the right leader for our Consumer Beauty transformation. Alexis, likewise, is a proven leader within Coty and his deep knowledge of our business and brands makes him the perfect fit to accelerate our growth on all continents.”

    Nabi continued: “Consumer Beauty is a critical pillar of our business. In times of uncertainty, the consumer beauty industry has an essential mission: the place where people can access the latest trends and innovations, find the best quality at an accessible price and experience the diversity of all kinds of beauties. That’s why we are excited that Coty has found two beauty champions who will enable our portfolio of meaningful brands - which include COVERGIRL, Sally Hansen, Rimmel, Bourjois, adidas and David Beckham, to name a few - to truly thrive.”

    In October, Coty announced the appointment of Isabelle Bonfanti as Chief Commercial Officer, Luxury. She boasts more than 30 years’ experience in international brand development and transformation, including 17 years in L’Oréal’s Luxury division. Bonfanti was joined by Jean-Denis Mariani as Chief Digital Officer, who joined from Guerlain as Coty continues to generate record e-commerce sales across its portfolio.

    About Coty Inc.

    Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com.

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $COTY

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2026$265.00Market Perform → Outperform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    4/8/2026$250.00Buy
    TD Cowen
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Coty Inc.
    $COTY
    1/14/2026$3.50Hold
    Jefferies
    Coty Inc.
    $COTY
    11/25/2025$3.60Neutral
    Rothschild & Co Redburn
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $JNJ
    $COTY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President - Consumer Beauty Von Bretten Gordon bought $200,287 worth of shares (83,000 units at $2.41), increasing direct ownership by 9% to 986,620 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    3/9/26 6:12:08 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Chief Financial Officer Mercier Laurent bought $13,250 worth of shares (5,000 units at $2.65), increasing direct ownership by 1% to 500,031 units (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    2/18/26 5:49:37 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Ballini Beatrice sold $55,300 worth of shares (7,000 units at $7.90) and bought $185,600 worth of shares (20,000 units at $9.28) (SEC Form 4)

    4 - COTY INC. (0001024305) (Issuer)

    11/18/25 7:44:01 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    $JNJ
    $COTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 134% to 24,911 units (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    5/4/26 4:58:59 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Eugene A.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    4/27/26 6:23:40 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director West Nadja

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    4/27/26 6:21:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    SEC Filings

    View All

    SEC Form SD filed by Coty Inc.

    SD - COTY INC. (0001024305) (Filer)

    5/29/26 4:19:59 PM ET
    $COTY
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SD filed by Johnson & Johnson

    SD - JOHNSON & JOHNSON (0000200406) (Filer)

    5/27/26 4:15:25 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Johnson & Johnson

    13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)

    5/13/26 4:29:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Johnson & Johnson from Market Perform to Outperform and set a new price target of $265.00

    5/13/26 7:59:34 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen resumed coverage on Johnson & Johnson with a new price target

    TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00

    4/8/26 8:36:42 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.  Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026

    6/5/26 7:25:00 PM ET
    $BLKB
    $BRBR
    $CABO
    Computer Software: Prepackaged Software
    Technology
    Packaged Foods
    Consumer Staples

    Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease

    Nipocalimab, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with Sjögren's disease while preserving immune function New exploratory analysis of Phase 2 study data shows a strong correlation between autoantibody levels and even greater clinical response rates of participants in the nipocalimab treatment group Previously reported data from the Phase 2 study showed nipocalimab reduced Sjögren's disease activity and severity, with potential to address systemic manifestations and the most burdensome patient-reported symptoms including dryness, fatigue and painNipocalimab is the only FcRn blocker

    6/3/26 12:03:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

    Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of MedicineCHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized

    5/31/26 8:27:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the w

    5/27/26 4:22:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 3.1% increase in the quarterly dividend, from $1.30 per share to $1.34 per share, marking the 64th year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026. The ex-dividend date is May 26, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, tr

    4/14/26 6:21:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson reports Q1 2026 results, raises 2026 outlook

    2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%* 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 Company increases 2026 guidance with estimated reported sales of $100.8 Billion or 7.0% at the midpoint, and adjusted EPS4 of $11.55 or 7.1% at the midpoint Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIP

    4/14/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    1/30/24 12:46:49 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $COTY
    Leadership Updates

    Live Leadership Updates

    View All

    Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 22, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from S&P MidCap 400 and S&P SmallCap 600 are no longer representative of the mid-cap and small-cap market space, respectively.  Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name       ActionCompany NameTickerGICS SectorJune 22, 2026

    6/5/26 7:25:00 PM ET
    $BLKB
    $BRBR
    $CABO
    Computer Software: Prepackaged Software
    Technology
    Packaged Foods
    Consumer Staples

    Johnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations

    Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Mr. Koors will report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph J. Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430443361/en/Ryan Koors, Vice President, Investor Relations, Johnson & Johnson, effective May 7, 2026. "Ryan's appointment underscores the deep bench of financial talent within Johnson & Johnson and our commitm

    4/30/26 8:02:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coty Revamps Board With Appointment of Five New Independent Directors

    Highly Accomplished Global Leaders Strengthen Board with Deep Beauty, Brand-Building and Financial Expertise to Advance Coty's Strategic Evolution Regulatory News: Coty Inc. (NYSE:COTY) (PARIS:COTY) ("Coty" or "the Company") today announced that its Board of Directors (the "Board") has appointed five new independent directors as part of a comprehensive Board refreshment. The new directors are Carsten Fischer, Alia Gogi, Robert Kunze-Concewitz, Maria Carla Liuni, and Stephanie Plaines. Mr. Kunze-Concewitz will serve as Chair of the Board's Remuneration Committee and Ms. Plaines will serve as Chair of the Board's Audit and Finance Committee. Mr. Fischer has also been named as the Board's

    3/18/26 4:30:00 PM ET
    $CLX
    $COTY
    $JLL
    Specialty Chemicals
    Consumer Discretionary
    Package Goods/Cosmetics
    Real Estate